Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmethylphenidate in Children With ADHD
NCT00141063Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmethylphenidate in attention deficit hyperactivity disorder (ADHD) (5 arms), sponsored by Novartis. Primary endpoint: Change in attention and deportment. Started Jun 2005; status: completed.
02
Drugs
dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00141063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141063.